Skip to main content

Table 3 Adverse events during the study

From: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

  N (%)
Mild adverse events 6 (3.7)
 Anxiety and hypercholesterolemia 1 (0.6)
 Abdominal pain, dyspepsia, and asthenia 1 (0.6)
 Irascibility and insomnia 1 (0.6)
 Pyrosis 1 (0.6)
 Sexual dysfunction 1 (0.6)
 Diarrhea 1 (0.6)
Grade 3–4 adverse events 0 (0)